T. K. Owonikoko

Concurrent Chemoradiation ± Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005

Kyndra S. Higgins, Chengping Hu, Helen J. Ross et al. · International Journal of Radiation Oncology*Biology*Physics · 2024 · 44 citations · Full text

Nrg Oncology/alliance Lu005, Medicine, Metronomic Therapy +7

Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC)

T. K. Owonikoko, R. G. Stoller, D. Petro et al. · Journal of Clinical Oncology · 2008 · 18 citations

Immunology, Pathology, Phase Ii Study +17

Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)

T. K. Owonikoko, K. Nackaerts, Tibor Csőszi et al. · Annals of Oncology · 2016 · 16 citations

Investigational Aurora, Medicine, Pharmacology +7

Abstract PD3-13: Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer

Kevin Kalinsky, JJ Harding, Angela DeMichele et al. · Cancer Research · 2018 · 13 citations

Abstract Pd3-13, Breast Oncology, Medicine +14

Comparison of survival for non-small cell lung cancer (NSCLC) between premenopausal and postmenopausal women: An analysis of the National Surveillance, Epidemiology and End Results (SEER) Database

Ana B. Oton, Chandra P. Belani, Chao Cai et al. · Journal of Clinical Oncology · 2006 · 12 citations

Epidemiology Of Cancer, Estrogen Receptor, Gynecology +21